Medical Information

Saphnelo is an innovative biological agent targeting type I interferon receptors, specifically designed for the treatment of moderate to severe systemic lupus erythematosus (SLE). The drug is administered via intravenous infusion, with a standard dose of 300mg once every 4 weeks. Attention should be paid to the risk of infection and medication precautions for special populations.

1. Mechanism of action

(1) Specifically binding to type I interferon receptor subunit 1, blocking downstream signaling pathways.

(2) Regulate overactive immune responses and reduce disease activity index.

2 Indications

(1) Suitable for adult SLE patients who have failed standard treatment.

(2) Especially for patients with high interferon characteristics, the effect is significant.

3 Usage and Dosage

(1) Administration method: Intravenous infusion for 30 minutes, to be completed by a medical institution.

(2) Standard protocol: 300mg/time, repeated every 4 weeks.

(3) Dose adjustment: Pause during severe infection and re evaluate after recovery.

4 Adverse reactions

(1) Common reactions: Upper respiratory tract infection (25%), injection site reaction (12%).

(2) Serious risks: opportunistic infections, exacerbation of depression (incidence<5%).

(3) Monitoring requirements: Screening for tuberculosis before medication and regular assessment of psychiatric symptoms.

5 Precautions

(1) Taboo: Prohibited for patients with active infections or a history of allergies.

(2) Special population: Due to limited data during pregnancy, it is recommended to suspend feeding during lactation.

(3) Vaccine contraindications: Avoid using live vaccines at the same time.